Upgrades
Ladenburg Thalmann upgraded the previous rating for Edison International (NYSE:EIX) from Sell to Neutral. Edison Intl earned $1.01 in the second quarter, compared to $0.94 in the year-ago quarter. The stock has a 52-week-high of $74.92 and a 52-week-low of $54.51. At the end of the last trading period, Edison Intl closed at $69.76.
For Hannon Armstrong Sustainable Infrastructure Capital Inc (NYSE:HASI), B of A Securities upgraded the previous rating of Neutral to Buy. Hannon Armstrong earned $0.53 in the second quarter, compared to $0.60 in the year-ago quarter. At the moment, the stock has a 52-week-high of $44.41 and a 52-week-low of $21.31. Hannon Armstrong closed at $23.12 at the end of the last trading period.
Janney Montgomery Scott upgraded the previous rating for Shore Bancshares Inc (NASDAQ:SHBI) from Neutral to Buy. For the second quarter, Shore Bancshares had an EPS of $0.25, compared to year-ago quarter EPS of $0.39. The current stock performance of Shore Bancshares shows a 52-week-high of $20.49 and a 52-week-low of $10.65. Moreover, at the end of the last trading period, the closing price was at $11.39.
Oppenheimer upgraded the previous rating for Redfin Corp (NASDAQ:RDFN) from Underperform to Perform. Redfin earned $0.25 in the second quarter, compared to $0.73 in the year-ago quarter. The stock has a 52-week-high of $17.68 and a 52-week-low of $3.08. At the end of the last trading period, Redfin closed at $10.16.
According to Raymond James, the prior rating for CareDx Inc (NASDAQ:CDNA) was changed from Market Perform to Outperform. CareDx earned $0.18 in the second quarter, compared to $0.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $24.54 and a 52-week-low of $6.22. CareDx closed at $9.35 at the end of the last trading period.
According to Morgan Stanley, the prior rating for Pharvaris NV (NASDAQ:PHVS) was changed from Equal-Weight to Overweight. Pharvaris earned $0.69 in the second quarter, compared to $0.40 in the year-ago quarter. The stock has a 52-week-high of $21.71 and a 52-week-low of $1.80. At the end of the last trading period, Pharvaris closed at $18.42.
RBC Capital upgraded the previous rating for Hexcel Corp (NYSE:HXL) from Sector Perform to Outperform. In the second quarter, Hexcel showed an EPS of $0.50, compared to $0.33 from the year-ago quarter. The current stock performance of Hexcel shows a 52-week-high of $79.08 and a 52-week-low of $50.25. Moreover, at the end of the last trading period, the closing price was at $69.11.
For NextDecade Corp (NASDAQ:NEXT), Stifel upgraded the previous rating of Hold to Buy. NextDecade earned $0.23 in the first quarter, compared to $0.14 in the year-ago quarter. The current stock performance of NextDecade shows a 52-week-high of $8.94 and a 52-week-low of $3.92. Moreover, at the end of the last trading period, the closing price was at $5.53.
See all analyst ratings upgrades.
Downgrades
According to Laidlaw & Co., the prior rating for Alaunos Therapeutics Inc (NASDAQ:TCRT) was changed from Buy to Hold. In the second quarter, Alaunos Therapeutics showed an EPS of $0.04, compared to $0.05 from the year-ago quarter. At the moment, the stock has a 52-week-high of $4.01 and a 52-week-low of $0.38. Alaunos Therapeutics closed at $0.39 at the end of the last trading period.
According to SVB Leerink, the prior rating for Galecto Inc (NASDAQ:GLTO) was changed from Outperform to Market Perform. Galecto earned $0.41 in the second quarter, compared to $0.67 in the year-ago quarter. The stock has a 52-week-high of $3.70 and a 52-week-low of $1.06. At the end of the last trading period, Galecto closed at $2.34.
For Chicken Soup for the Soul Entertainment Inc (NASDAQ:CSSE), Craig-Hallum downgraded the previous rating of Buy to Hold. For the second quarter, Chicken Soup for the Soul had an EPS of $1.50, compared to year-ago quarter EPS of $1.28. The stock has a 52-week-high of $13.44 and a 52-week-low of $0.94. At the end of the last trading period, Chicken Soup for the Soul closed at $1.01.
For Design Therapeutics Inc (NASDAQ:DSGN), Wedbush downgraded the previous rating of Outperform to Neutral. Design Therapeutics earned $0.36 in the second quarter, compared to $0.27 in the year-ago quarter. The stock has a 52-week-high of $26.30 and a 52-week-low of $4.90. At the end of the last trading period, Design Therapeutics closed at $7.33.
According to Alliance Global Partners, the prior rating for Chicken Soup for the Soul Entertainment Inc (NASDAQ:CSSE) was changed from Buy to Neutral. Chicken Soup for the Soul earned $1.50 in the second quarter, compared to $1.28 in the year-ago quarter. The stock has ...Full story available on Benzinga.com
Benzinga